Marinus Pharmaceuticals Added to NASDAQ Biotechnology Index
December 13 2017 - 7:30AM
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”), a
biopharmaceutical company dedicated to the development of
innovative therapeutics to treat epilepsy and neuropsychiatric
disorders, today announced that it has been selected for addition
to the NASDAQ Biotechnology Index®, which will become effective
prior to the open of U.S. markets Monday, December 18, 2017.
The NASDAQ Biotechnology Index (NBI) contains
securities of NASDAQ-listed companies classified according to the
Industry Classification Benchmark as either Biotechnology or
Pharmaceuticals which also meet other eligibility criteria.
Companies in the NBI must meet eligibility requirements, including
minimum market capitalization, and average daily trading volume,
among other criteria. The NASDAQ Biotechnology Index is
re-ranked annually and forms the basis for a number of Exchange
Traded Funds (ETFs) including the iShares NASDAQ Biotechnology ETF.
For more information about the NASDAQ Biotechnology Index
visit https://indexes.nasdaqomx.com.
About Marinus
Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a
biopharmaceutical company dedicated to the development of
ganaxolone, which offers a new mechanism of action, demonstrated
efficacy and safety, and convenient dosing to improve the lives of
patients suffering from epilepsy and neuropsychiatric disorders.
Ganaxolone is a positive allosteric modulator of GABAA that acts on
a well-characterized target in the brain known to have both
anti-seizure and anti-anxiety effects. Ganaxolone is being
developed in three different dose forms (IV, capsule and liquid)
intended to maximize therapeutic reach to adult and pediatric
patient populations in both acute and chronic care settings.
Marinus is currently evaluating ganaxolone in women with postpartum
depression and preparing to initiate studies in children with CDKL5
deficiency disorder and patients with status epilepticus, both of
which are orphan indications. For more information visit
www.marinuspharma.com. Please follow us on Twitter:
@MarinusPharma.
Forward-Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Marinus, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Words such as “may”, “will”, “expect”, “anticipate”,
“estimate”, “intend”, “believe”, and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking
statements. Examples of forward-looking statements contained
in this press release include, among others, statements regarding
our interpretation of preclinical studies, development plans for
our product candidate, including the development of dose forms, the
clinical trial testing schedule and milestones, the ability to
complete enrollment in our clinical trials, interpretation of
scientific basis for ganaxolone use, timing for availability and
release of data, the safety, potential efficacy and therapeutic
potential of our product candidate and our expectation regarding
the sufficiency of our working capital. Forward-looking statements
in this release involve substantial risks and uncertainties that
could cause our clinical development programs, future results,
performance or achievements to differ significantly from those
expressed or implied by the forward-looking statements. Such
risks and uncertainties include, among others, the uncertainties
inherent in the conduct of future clinical trials, the timing of
the clinical trials, enrollment in clinical trials, availability of
data from ongoing clinical trials, expectations for regulatory
approvals, the attainment of clinical trial results that will be
supportive of regulatory approvals, and other matters, including
the development of formulations of ganaxolone, and the availability
or potential availability of alternative products or treatments for
conditions targeted by the Company that could affect the
availability or commercial potential of our drug candidates.
Marinus undertakes no obligation to update or revise any
forward-looking statements. For a further description of the
risks and uncertainties that could cause actual results to differ
from those expressed in these forward-looking statements, as well
as risks relating to the business of the Company in general, see
filings Marinus has made with the Securities and Exchange
Commission.
CONTACT: Lisa M. CaperelliExecutive Director,
Investor & Strategic RelationsMarinus Pharmaceuticals,
Inc.484-801-4674lcaperelli@marinuspharma.com
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Sep 2023 to Sep 2024